A new study of almost 2,000 patients shows that testing for the activity of two genes could pick out women who are at increased risk of dying from their breast cancers.
Women whose tumours had a specific pattern of activity in the two genes were three times as likely to die within 10 years as others with a different pattern of activity.
Scientists at The Institute of Cancer Research, London, spotted the pattern of gene activity among breast cancer cells with a particular ability to escape from the glue that normally holds them in place.
They believe the genes could play a key role in releasing cells from this glue - known as the extracellular matrix, so they can spread round the body.
The study looked at breast cancer cells that were positive for the protein HER2 - the target for the drug Herceptin, which is found in around 20 per cent of tumours.
The ICR researchers developed a new image-based screening technique in order to identify cancer cells that didn't stick to the protein laminin, which helps build scaffolding around cells to glue them together.
They found that these cells tended to have high activity in a gene called F12 and low activity in another called STC2.
When the researchers analysed the same genes among 1,964 breast cancers, they found that this pattern of activity was strongly linked to survival.
Women whose tumours had high F12 activity and low STC2 activity had a 32 per cent chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10 per cent chance of dying.
More research is now needed, to establish how these genes could interfere with the extracellular matrix and help cancer cells grow and spread.
"Survival rates for breast cancer are now much higher than they were a few decades ago, but the disease remains deadly once it has spread round the body. Our study sheds light on how cancer cells unstick themselves from healthy tissue, and it could help pick out women at high risk of their cancer spreading and becoming fatal," said study leader Dr Paul Huang.
"We found that the activity of two genes which may help control how tightly cells are glued together is linked to breast cancer survival. If the results are confirmed in larger studies, it could give us a new way of assessing women's survival chances in the clinic, and adjusting treatment accordingly," Huang added.
The study has been published in Oncotarget.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
